Washoe County sees two Mpox cases; officials urge vaccination for those at higher risk Northern Nevada Public Health has confirmed two cases of mpox in Washoe County, prompting public health officials to emphasize the importance of vaccination for individuals at elevated risk of exposure. While the general public's risk remains low, officials are urging heightened precautions for those in vulnerable groups. The cases have drawn attention beyond Nevada, with global medical experts highlighting the significance of the development. Melvin Sanicas, global medical lead for vaccines at Bavarian Nordic, stated that the detection in Washoe County has been widely reported internationally, underscoring the need for vigilance. Mpox, previously known as monkeypox, is a viral infection that spreads through prolonged skin-to-skin contact. Health authorities have also warned that the virus can transmit via contaminated personal items such as clothing or bedding. Symptoms typically include a rash, fever, swollen lymph nodes, and fatigue. Dr. Chad Kingsley, district health officer for Northern Nevada Public Health, explained that mpox belongs to the same "pox" family as other well-known illnesses, including chickenpox, measles, and smallpox. He noted that the virus can present similarly to these conditions, though its transmission methods and symptoms differ. Public health officials are urging individuals at higher risk of exposure to take proactive measures to protect themselves. Kingsley emphasized that vaccination is one of the most effective tools to prevent illness and curb the spread of the virus. However, he acknowledged that eligibility criteria may apply due to limited vaccine availability.#bavarian_nordic #washoe_county #northern_nevada_public_health #melvin_sanicas #dr_chad_kingsley
Bolivia's Chikungunya Outbreak Continues to Prompt Travel Advisories The chikungunya outbreak in Bolivia's Santa Cruz department has seen a slight decline in new cases, according to the Departmental Health Service (SEDES). Epidemiologist Carlos Hurtado reported that the latest epidemiological week recorded 655 confirmed cases, a reduction of about 300 compared to the prior week. This brings the total number of cases in Santa Cruz, the primary epicenter of the outbreak, to 4,283 as of March 9, 2026. Despite the drop, the positivity rate remains high at 51%, meaning over half of those tested are infected with the East/Central/South African genotype of the virus. The U.S. Centers for Disease Control and Prevention (CDC) has issued a Level 2 Travel Health Notice for Santa Cruz and Cochabamba, urging travelers to take precautions such as using insect repellent, wearing protective clothing, and considering vaccination where available. Bolivia is not the only country experiencing chikungunya cases this year. Global data indicate over 29,000 cases and 85 fatalities have been reported by early March. The main vaccine available in the U.S. and select countries is VIMKUNYA®, a non-live virus-like particle vaccine developed by Bavarian Nordic A/S. Approved by the U.S. FDA in 2025, the vaccine is now accessible at travel clinics and pharmacies. The outbreak highlights ongoing challenges in managing mosquito-borne diseases. While Bolivia's situation shows some improvement, the broader context of the epidemic underscores the need for continued vigilance. Travelers are advised to stay informed about regional health advisories and take preventive measures to reduce the risk of infection.#chikungunya #bolivia #santacruz #cdc #bavarian_nordic
